Meeting
2018 Gastrointestinal Cancers Symposium
Safety for trifluridine/tipiracil (TAS-102) with bevacizumab combination in patients with refractory metastatic colorectal cancer in real-world clinical practice: The single-institutional experience.
Authors
Kayo Yasuda
National Cancer Center East, Kashiwa, Japan
Kayo Yasuda , Daisuke Kotani , Yasutoshi Kuboki , Shota Fukuoka , Hideaki Bando , Akihito Kawazoe , Yoshiaki Nakamura , Kohei Shitara , Takayuki Yoshino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 865)
DOI
10.1200/JCO.2018.36.4_suppl.865
Abstract #
865
Poster Bd #
P17
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
First Author: Hirokazu Shoji
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.
First Author: Patrick M Boland
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Multicenter retrospective study of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) for vulnerable patients with pretreated metastatic colorectal cancer (mCRC): WJOG14520G (TWILIGHT).
First Author: Seiichiro Mitani
Poster
2019 Gastrointestinal Cancers Symposium
Multicenter phase Ib/ II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study).
First Author: Masahito Kotaka